181 related articles for article (PubMed ID: 20490796)
1. Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials.
Zaremba T; Thomas H; Cole M; Plummer ER; Curtin NJ
Cancer Chemother Pharmacol; 2010 Sep; 66(4):807-12. PubMed ID: 20490796
[TBL] [Abstract][Full Text] [Related]
2. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
Ji J; Kinders RJ; Zhang Y; Rubinstein L; Kummar S; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2011; 6(10):e26152. PubMed ID: 22028822
[TBL] [Abstract][Full Text] [Related]
3. Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action.
Wesierska-Gadek J
J Cell Biochem; 2005 Aug; 95(5):1012-28. PubMed ID: 15861398
[TBL] [Abstract][Full Text] [Related]
4. The role of Kif4A in doxorubicin-induced apoptosis in breast cancer cells.
Wang H; Lu C; Li Q; Xie J; Chen T; Tan Y; Wu C; Jiang J
Mol Cells; 2014 Nov; 37(11):812-8. PubMed ID: 25377255
[TBL] [Abstract][Full Text] [Related]
5. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.
Pacher P; Liaudet L; Bai P; Virag L; Mabley JG; Haskó G; Szabó C
J Pharmacol Exp Ther; 2002 Mar; 300(3):862-7. PubMed ID: 11861791
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.
Mariano G; Ricciardi MR; Trisciuoglio D; Zampieri M; Ciccarone F; Guastafierro T; Calabrese R; Valentini E; Tafuri A; Del Bufalo D; Caiafa P; Reale A
Oncotarget; 2015 Jun; 6(17):15008-21. PubMed ID: 25938539
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-induced testicular damage is related to PARP-1 signaling molecules in mice.
Gungor-Ordueri NE; Kuscu N; Tasatargil A; Burgucu D; Karacan M; Celik-Ozenci C
Pharmacol Rep; 2019 Aug; 71(4):591-602. PubMed ID: 31174020
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
Feng X; Koh DW
Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin induces early embryo apoptosis by inhibiting poly(ADP ribose) polymerase.
Wang QL; Sun SC; Han J; Kwak YC; Kim NH; Cui XS
In Vivo; 2012; 26(5):827-34. PubMed ID: 22949597
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.
Pacher P; Liaudet L; Mabley JG; Cziráki A; Haskó G; Szabó C
Int J Mol Med; 2006 Feb; 17(2):369-75. PubMed ID: 16391839
[TBL] [Abstract][Full Text] [Related]
12. Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
Mégnin-Chanet F; Bollet MA; Hall J
Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763
[TBL] [Abstract][Full Text] [Related]
13. Effect of hyperthermia and doxorubicin on nucleoid sedimentation and poly (ADP-ribose) polymerase activity in L1210 cells.
Daugherty JP; Simpson TA; Mullins DW
Cancer Chemother Pharmacol; 1988; 21(3):229-32. PubMed ID: 3129205
[TBL] [Abstract][Full Text] [Related]
14. A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation.
Aldinucci A; Gerlini G; Fossati S; Cipriani G; Ballerini C; Biagioli T; Pimpinelli N; Borgognoni L; Massacesi L; Moroni F; Chiarugi A
J Immunol; 2007 Jul; 179(1):305-12. PubMed ID: 17579050
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Yang SX; Kummar S; Steinberg SM; Murgo AJ; Gutierrez M; Rubinstein L; Nguyen D; Kaur G; Chen AP; Giranda VL; Tomaszewski JE; Doroshow JH;
Cancer Biol Ther; 2009 Nov; 8(21):2004-9. PubMed ID: 19823047
[TBL] [Abstract][Full Text] [Related]
16. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
Wang B; Qian H; Yiu SM; Sun J; Zhu G
Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.
Zaremba T; Thomas HD; Cole M; Coulthard SA; Plummer ER; Curtin NJ
Biochem J; 2011 Jun; 436(3):671-9. PubMed ID: 21434873
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
Vormoor B; Curtin NJ
Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction.
Szántó M; Rutkai I; Hegedus C; Czikora Á; Rózsahegyi M; Kiss B; Virág L; Gergely P; Tóth A; Bai P
Cardiovasc Res; 2011 Dec; 92(3):430-8. PubMed ID: 21921080
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.
He JX; Yang CH; Miao ZH
Acta Pharmacol Sin; 2010 Sep; 31(9):1172-80. PubMed ID: 20676117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
